Is Painchek [ASX:PCK] about to be the next breakout stock? Part 2 of 3.

The InsideMarket Private Fund owns shares in Painchek at the time of publishing this post. We have not received any payment from the company for this coverage. More disclosure at end of post.



Painchek {ASX:PCK] is a business on the brink of exponential growth, according to its CEO Philip Daffas.


In part two of my series on Painchek, Daffas explains how their deal with the Australian Federal Government will positively impact the business for years.


The Federal Government has committed five million dollars to help fund the use of Painchek in 100,000 hospitals beds for a year.


We also discuss his recent trip to Europe, the opening of a sales office in Britain, and the discussions he is having with Phillips Health Care.


In the final part of the series, which will be released next week, we will discuss the infant Painchek app and find out just how much potential it really has.


Let me know what you think of Painchek (ASX:PCK) or if you'd like me to look at any other tech companies.


PART 1

The InsideMarket Private Fund owns shares in Painchek at the time of publishing this post. We have not received any payment from the company for this coverage. Disruptive technology stocks should be considered very speculative, high-risk, and extremely volatile. There are significant risks inherent in developing new technologies that are not discussed here. You should always seek professional advice before considering any share purchase or sale. Please read our full disclaimer.

86 views
  • LinkedIn Social Icon
  • Twitter Social Icon

Through our InsideMarket Tech Fund we may have holdings in companies we report on. However, we do not receive any payment for coverage on insidemarket.net